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This study presents a limitation regarding the subjectivity inherent to costs determi-
nation based on answers given by the HP. Moreover values may be underestimated 
due to lack of information regarding fixed costs.
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ResouRCe use of NoN-small Cell luNg CaNCeR iN slovakia
Ondrusova M.1, Psenkova M.1, Berzinec P.2, Basso F.3
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Objectives: Data on economic burden of advanced or metastatic non-small cell lung 
cancer (NSCLC) are lacking in Slovakia. Therefore, the objective of this cost of illness 
study was to measure the resource utilisation and the costs associated with treating 
advanced or metastatic NSCLC in Slovakia and provide a basis for cost-effectiveness 
evaluations. MethOds: The project was run in two phases: in the first phase an 
Expert panel took part in the survey and developed the diagnostic and treatment 
algorithms to reflect the local medical practice and quantify the use of resources 
associated with anticancer drug treatment, management of adverse events and best 
supportive care. Then, in the second step, 2012 management costs were applied to the 
resources. All types of health care used in the NSCLC management were evaluated 
(outpatient and inpatient visits, diagnostics, prescription drugs and examinations). 
The analysis was performed from the Slovakian health insurance perspective reflect-
ing direct medical costs only. The structure of cost data follows the requirements 
of pharmaco-economic modelling in NSCLC. Results: Monthly costs of advanced 
or metastatic NSCLC management during the active treatment (before progression) 
count for € 1055.67, during the disease progression € 1101.21 and on the best supporting 
care € 1561.22. The most frequent regimens were cisplatin+gemcitabine (20.6%) and 
cisplatine+pemetrexed (19.1%) in the first line, erlotinib (49.1%) in the second line and 
gemcitabine (29.6%) in the third line. The most costly side effects were renal toxic-
ity (€ 1060.85), febrile neutropenia (€ 902.92), hemoptysis (€ 717.08), anaemia (€ 668.84), 
pain (€ 631.34), leukopenia/neutropenia (€ 629.58), dyspnoe (€ 628.35), thrombocytope-
nia (€ 578.60), nausea/vomiting (€ 562.72) and fatigue (€ 523.19). cOnclusiOns: Cost-
effectiveness must be demonstrated in order to get reimbursement in Slovakia and 
local resource use data are key drivers for health economic modelling and can guide 
resource allocation decisions in NSCLC. This study provides important information 
to support these decisions.
CaNCeR – Patient-Reported outcomes & Patient Preference studies
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adheReNCe Rates foR iNtRaveNous ChemotheRaPy RegimeNs to tReat 
ColoN CaNCeR
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Objectives: It is widely thought that adherence rates to intravenous (IV) chemo-
therapy regimens for colon cancer are high. However, there are no known formal 
assessments of this issue. MethOds: A retrospective analysis was performed using 
the Optuminsight Oncology claims database. Patients aged 18 years and older, diag-
nosed with CRC between July 1, 2004 and December 31, 2010, who were insured by a 
commercial health plan were included in the study. Adherence to the following IV 
chemotherapy regimens was assessed using the National Comprehensive Cancer 
Network (NCCN) guidelines as the standard for expected cycle/regimen duration: 
FOLFOX, FOLFOX+bevacizumab, FOLFIRI, and FOLFIRI+bevacizumab. Adherence 
was assessed using the medication possession ratio (MPR), calculated as the num-
ber of days a patient was covered by their chemotherapy regimen, according to 
NCCN guidelines, divided by the number of days elapsed from the first to the last 
infusion of that regimen. Results: A total of 46,941 chemotherapy cycles in 6,880 
patients were analyzed. Overall, adherence rates to IV chemotherapy was fairly 
high, with mean MPR ranging between 0.84 and 0.88 for these regimens. However, 
a substantial proportion of patients for each regimen experienced low adherence. 
Twenty five percent of patients receiving FOLFOX, FOLFOX+bevacizumab, and 
FOLFIRI+bevacizumab regimens experienced MPR< 0.8. Additionally, approximately 
35% of patients receiving FOLFIRI experienced an MPR< 0.8. At least 10% of patients 
receiving FOLFOX regimens had an MPR less than 0.7; while at least 10% of patients 
receiving FOLFIRI regimens had an MPR of less than 0.6. cOnclusiOns: Although 
overall rates of adherence were fairly high, a substantial subpopulation experienced 
low adherence to each of these IV regimens per NCCN guideline recommendations. 
The reasons for the low adherence rates need to be explored as this could have an 
impact on efficacy. These results also highlight the drawback of relying solely on 
summary statistics at the population level.
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PeRsisteNCe iN PatieNts with BReast CaNCeR tReated with tamoxifeN 
oR aRomatase iNhiBitoRs- aNalysis Based oN oNCology aNalyzeR 
dataBase
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Objectives: Lack of non-compliance is often underestimated in breast cancer 
treatment. The aim of our study was to analyze the persistence with tamoxifen 
(TAM) and aromatase inhibitors (AI) in women with breast cancer (BC) and to 
identify reasons of treatment discontinuation and determinants of non-per-
sistency. MethOds: We used data of the Oncology Analyzer database, which 
includes individual information on patient history related to the treatment of 
patients across all cancer types. This enables a complete overview of cancer 
patient care from diagnosis onward, facilitating research in areas such as treat-
ment changesn, dosing and regimen compliance, market sizing and off-label use. 
We identified 7063 breast cancer patients with a start of TAM or AI therapy from 
1990 until 2011 and with a treatment duration of at least 365 days. Results: After 
tion). cOnclusiOns: Disability in cancer survivors is very common and is more 
severe than in other diseases.
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imPaCt of NuRsiNg aNd PhaRmaCy CaRe BetweeN CaPeCitaBiNe aNd 
5-fluoRuRaCil RegimeNs iN the maNagemeNt of advaNCed esoPhago-
gastRiC CaNCeR iN hoNg koNg
Lee V.W.Y.1, Yao R.2, Yip E.2, Law K.3, Tang G.3, Zhou K.R.1
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Objectives: To compare the possible time savings from reduction of nursing and 
pharmacy time to manage advanced esophago-gastric cancer (AEGC) patients using 
capecitabine-based regimens versus traditional 5-FU based intravenous (IV) chemo-
therapy in the Hong Kong public hospital setting. MethOds: This was a time-and-
motion study conducted in 2 public hospitals of Hong Kong based on the simulation 
of previously data on both capecitabine-based regimen (XELOX and XP) and IV 
5-FU-based regimen (FOLFOX and FP). The preparation, dispensing and administration 
time for XELOX, XP, FOLFOX and FP were compared. The capital item utilization includ-
ing hospital bed, infusion pump etc and length of patient attendance were recorded. 
Each subject was based on 24-week cycle in the analysis. The projected cost saving 
in nursing and pharmacy time was estimated if all AEGC in Hong Kong were pre-
scribed capecitabine-based regimen. Results: The average nursing time for FOLFOX 
and FP was 83.7 and 83.4 minutes versus XELOX and XP was 33.7 and 39.8 minutes 
respectively. The average pharmacy dispensing time for FOLFOX and FP was 25.3 and 
71.4 minutes versus XELOX and XP was 18.7 and 19.9 minutes respectively. The total 
time saved for each patient for a 24-week cycle in FOLFOX versus XELOX was 734.8 
minutes in nursing and 154.0 minutes in pharmacy as well as in FP versus XP was 
182 minutes in nursing and 269.2 minutes in pharmacy. Nursing and pharmacy could 
potentially spare 3.3 full time equivalent (FTE) and 1.5 FTE if all AEGC patients were 
converted to capecitabine-based chemotherapy. cOnclusiOns: Capecitabine-based 
chemotherapy regimens saved in both nursing and pharmacy time as compared to 
traditional 5-FU based IV chemotherapy in the Hong Kong public hospital setting.
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woRkfoRCe PaRtiCiPatioN aNd PRoduCtivity losses afteR head aNd 
NeCk CaNCeR
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Objectives: There has been no estimate of the productivity losses associated with 
head and neck cancer (HNC) conducted using bottom-up data, or beyond prema-
ture mortality. The aim of this work is to investigate workforce participation, and 
estimate the productivity losses associated with temporary and permanent work 
absence, reduced work hours, and premature mortality in individuals with HNC in 
Ireland. MethOds: Survey data were collected from a cancer registry identified cohort 
of individuals in Ireland diagnosed with head and neck cancer between January 1994 
and December 2011. Data collected included employment status at time of diagnosis 
and workforce participation patterns following diagnosis. These data were combined 
with population-level survival estimates and national wage data to estimate the value 
of temporary and permanent work absence, reduced work hours and premature mor-
tality using a Human Capital Approach. Results: Of the survey respondents, 276 were 
in paid work at the time of diagnosis. 88% had time off following diagnosis, with 63% of 
these returning to work. The mean (median) time off work was 9 months (6 months), 
range of 0 to 65 months. Seventy percent of individuals returning to work reported 
reducing the hours they worked, by an average of 20 hours per week. Preliminary 
results show the average productivity losses per person associated with temporary 
and permanent work absence and reduced work hours are € 222,000. Productivity losses 
associated with premature mortality and the results of sensitivity analyses to test 
discount and wage growth rates will also be presented. cOnclusiOns: Head and 
neck cancer and its treatment can have a profound impact on workforce participation. 
This affects not only the individuals’ and their families, but also society in terms of 
productivity costs. These costs should be considered in economic evaluations of cancer 
treatments and health service delivery in this population.
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hosPital ResouRCes CoNsumPtioN assoCiated with tRastuzumaB 
tReatmeNt iN BReast CaNCeR iN PoRtugal
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Objectives: Determine the costs associated with the preparation and adminis-
tration, considering the material resources (MR) consumption and time spent by 
the health care professionals (HP), of Her2 positive breast cancer treatment with 
trastuzumab intravenous (iv) and to estimate the difference compared with a subcu-
taneous (sc) formulation. MethOds: Data were collected in face to face interviews 
with the pharmacist and nurse responsible for the preparation and administration 
of trastuzumab in each hospital. The cost of the HP time was calculated by multi-
plying the value of each HP hour by the average time of each procedure; MR costs 
were determined based on the values presented in official sources or in price table 
provided by the manufacturer. Results: Five public and two private Hospitals from 
mainland Portugal, with an average of 12 patients with HER2 + breast cancer treated 
with trastuzumab iv, per week, participated in the study. The average time spent by 
the HP in trastuzumab preparation and administration was 79 minutes for iv and 18 
minutes for sc. Per treatment cycle, the estimated average overall cost of each treat-
ment was € 43.22 (HP - € 26.01; MR - € 17.21) for iv, and € 3.18 (HP - € 3.13; MR - € 0.05) for 
sc. Considering the total course of treatment (18 cycles), the treatment with tras-
tuzumab iv is estimated at € 777.96 versus € 57.19 on sc treatment. cOnclusiOns: 
Trastuzumab sc formulation would potentially allow savings of approximately € 720 
per patient, and provide an important benefit to the patients. Trastuzumab sc would 
also contribute to maximize the efficiency and effectiveness of health resources. 
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cycles of treatment in the same health state. MethOds: The GRID study included a 
double-blinded phase, plus an open-label regorafenib phase for those whose disease 
progressed. The EQ-5D index was evaluated using paired-samples comparison as 
the primary analysis, and repeated measures as a sensitivity analyses. Results: 
A total of 185 subjects were included; 63% males, with an overall average age of 58 
years; 55% received study treatment as 3rd-line, the rest as 4th-line or later. 67% 
were randomized to receive regorafenib as initial double-blind therapy. Average 
utility at baseline was 0.767 units. There were no differences in baseline charac-
teristics or EQ-5D for either treatment arm, or those whose disease progressed. 
The paired-samples analysis compared progression-free EQ-5D index versus any 
first, post-progression assessment. Of those with available data (N= 77) there was a 
difference of -0.120 units (p= 0.001). In the repeated analysis, the Δ -EQ-5D between 
progression-free disease and disease progression (in double-blind phase) was -0.041 
units (p= 0.051). The mean EQ-5D index following discontinuation of open-label 
treatment due to secondary progression was much lower, with a difference of -0.231 
units (p< 0.001). Whilst adjusting for disease status and treatment, the cycle number 
did not significantly influence the EQ-5D index (p= 0.341). cOnclusiOns: Heath-
related utility remained stable over successive treatment cycles after controlling 
for disease status and treatment type, suggesting that for subjects treated with 
regorafenib who remained progression-free, that active treatment did not lead to 
deterioration in utility. Due to the cross-over design, the repeated measures analysis 
did not contain a homogenous, group of people whose disease had progressed. Thus, 
the paired-sample analysis provides a better estimate of utility.
PCN154
assoCiatioNs BetweeN oveRall CaRe exPeRieNCe RatiNgs aNd utility 
aNd PsyChologiCal well-BeiNg iN meN ReCeNtly diagNosed with 
PRostate CaNCeR: fiNdiNgs fRom a PoPulatioN-Based study
Hennessy M., O’Leary E., Comber H., Drummond F.J., Sharp L.
National Cancer Registry Ireland, Cork, Ireland
Objectives: Patient experience is increasingly recognised as an important measure 
of quality of care. A few studies have suggested that patients who report higher 
levels of satisfaction with care also have higher quality-of-life and higher psycho-
logical wellbeing, and are more likely to cooperate with treatment. In Ireland, this 
area is under-researched. The PiCTure 2 study aimed to assess the care experiences 
of men recently diagnosed with prostate cancer – the most common cancer among 
men in Ireland - and investigate associations between experiences and health-
related quality-of-life (utility) and psychological wellbeing (depression, anxiety 
and distress). MethOds: Men diagnosed with invasive prostate cancer (ICD10 C61) 
5-20 months prior to study commencement were identified through the National 
Cancer Registry. The patient experience questionnaire was based on the Prostate 
Care Questionnaire (Baker et al. 2007), modified for Ireland. Utility and psychologi-
cal wellbeing were assessed using the EQ5D-5L and Depression Anxiety and Stress 
Scale (DASS-21). The questionnaire was administered by post to 2,180 men during 
January-April 2013. EQ5D-5L responses were converted to EQ5D-3L health states 
and valued with UK valuations. Results: A total of 1499 valid questionnaires were 
received (response rate= 70%). Men rated their overall care very highly; however, 
there were variations with those (i) further from diagnosis, (ii) in poorer health, 
(iii) younger, (iv) with third level education and (v) with private health insurance 
significantly more likely to report poorer care experiences. Almost half of men 
reported maximum utility scores; one-fifth had depression, one-fifth anxiety and 
one-eighth stress. Lower global experience scores were significantly associated with 
lower utility values and poorer psychological well-being (p< 0.001). cOnclusiOns: 
While men recently diagnosed with prostate cancer report quite high overall care 
experience ratings, variations were reported and associations with lower utility and 
psychological well-being were observed. These results provide further rationale for 
initiatives to improve quality of care.
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Objectives: The European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is one of the most com-
monly used quality of life instruments in clinical trials of anti-cancer agents. Here 
we present an algorithm for mapping between the QLQ-C30 and EQ-5D prefer-
ences in an adult population with advanced soft tissue sarcoma (aSTS) who par-
ticipated in the PALETTE trail, building upon mapping work performed in other 
tumours. MethOds: Data from the PALETTE trial assessing pazopanib versus 
placebo for the treatment of aSTS (n= 369) was used, where EQ-5D was assessed at 
baseline and week 4, and the QLQ-C30 at baseline plus weeks 4, 8 and 12. Ordinary 
least squares (OLS) and generalised linear model regression using a generalised 
estimating equations (GLM/GEE) approach was employed with the EQ-5D disu-
tility value as the dependent value. A variety of model forms were tested with 
different link functions and error term distributions, as well as using two stage 
models and including factors other than QLC-C30 terms (i.e., age, sex, ECOG sta-
tus). Results: There was relatively little variability in the root mean square error 
(RMSE) and R-squared across 28 different models tested, with the RMSE ranging 
from 0.16 to 0.18 and the R-squared ranging from 0.54 to 0.63. Using GLM/GEE 
vs. OLS, adding non QLQ-C30 terms, two-stage models, and squared terms for 
QLQ-C30 scores all improved R2, albeit slightly. All the models overestimated the 
disutility for assessments with zero disutility and underestimated the disutil-
ity for assessments with large disutilities, as has commonly been reported for 
such algorithms. cOnclusiOns: The mapping algorithms tested had reasonable 
predictive validity. These algorithms were used in cost-effectiveness evaluations 
of pazopanib in aSTS patients and may be useful for future cost-effectiveness 
evaluations of other therapies for this indication.
one year of follow up, 11.2% of TAM, and 18.4% of AI treated patients discontinued 
their treatment. In these patients with , the reasons for stopping were: progres-
sive disease including local and distant progression (68.1%), side effects (15.5%), 
patient’s choice (8.6%) and other reasons (7.8%). The multivariate hazard ratios of 
the cox regression models showed that patients younger than 50 were most likely 
to discontinue initial therapy when compared with the reference group of women 
over 70 years of age (HR: 2.30, p= 0.01). In contrast, patients treated in gynae-
cologist or oncologist practice had significantly longer persistence than patients 
who obtained their prescriptions in general hospital or academic cancer facility 
(HR: 0.47, p= 0.02). Additionally, patients with therapy initiation in gynecological 
practices had significantly longer persistence than in oncological practice (HR: 
0.68, p= 0.04). Additionally, metastases were associated with strongly increased 
risk of treatment discontinuation (HR: 3.81, p< 0.01). cOnclusiOns: The propor-
tion of breast cancer patients with therapy discontinuation within first year after 
therapy start is high and needs to be significantly increased to improved outcome 
in clinical practice.
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Chevalier J.1, Le Lay K.2, de Pouvourville G.1
1ESSEC Business School, Cergy-Pontoise Cedex, France, 2Boehringer Ingelheim France, Paris Cedex 
13, France
Objectives: Lung cancer has an important impact on Health related Quality of Life 
(HRQoL). LUCEOR2 is a multi-country prospective study which aimed to measure 
HRQoL and EQ-5D utility values in Non Small Cell Lung Cancer patients (NSCLC). 
Previous results presented utility values calculated on the whole LUCEOR2 popula-
tion and on the French subgroup using the UK tariff for the EQ-5D. Our aim was 
to calculate utility values with the French tariff for the application in French cost-
effectiveness studies. MethOds: Data from the LUCEOR2 study that included all 
patients from participating countries which provided a meaningful sample size for 
data analysis. Patients were stratified in 7 health states defined by the response of 
treatment (progressive or stable) and the line of treatment (1st, 2nd, 3rd/4thand BSC).
EQ-5D health states were valued using the French tariff. Results: A total of 319 
patients were recruited in LUCEOR2, HRQoL were available for 258 of them (73 in 
France). Mean utilities for progression-free patients on 1st, 2nd and 3rd/4th lines were 
0.690 (n= 116; standard deviation [sd]: 0.258), 0.697(n= 46; sd: 0.221) and 0.609(n= 25; 
sd: 0.324) respectively. For patients with progressive disease, values were 0.608(n= 26; 
sd: 0.237), 0.550(n= 17; sd: 0.353) and 0.418(n= 21; sd: 0.399). Overall, patients with 
progressive disease had lower mean utility than patients with stable disease (0.530 
vs. 0.682 ; p= 0.001). Utilities calculated using the French EQ-5D tariff are lower than 
the utilities calculated using the UK tariff. cOnclusiOns: This study presents the 
French utility values for patients with NSCLC. It demonstrates the impact of the 
disease on the HRQol. Further investigations will be made on the potential differ-
ences in scores between countries.
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RefRaCtoRy (R/R) hodgkiN lymPhoma (hl) aNd systemiC aNaPlastiC 
laRge-Cell lymPhoma (salCl) iN mexiCo aNd BRazil
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Company, Cambridge, MA, USA
Objectives: Benefits of treatment can be measured by utility values. Health utili-
ties typically range between 0 (dead) and 1 (full health) and reflect health-related 
quality of life (HRQL) in a given health state. Societal values for health states can 
be captured using the time trade-off (TTO) methodology. Currently, no values 
exist for health states depicting stages of R/R HL and sALCL for Latin American 
countries. The aim of this study was to collect utility values from members of 
the public in Mexico and Brazil for R/R HL and sALCL health states. MethOds: 
Health states were developed using recognized methods, including a litera-
ture review, patient and clinician interviews, and cognitive debriefing. States 
included stages of R/R HL and sALCL (complete response [CR], partial response 
[PR], stable disease, and progressive disease), and adverse events (AEs) including 
B-symptoms, acute/chronic graft-versus-host disease (GVHD), and grade I/II or 
grade III peripheral sensory neuropathy (PSN). Members of the public in Mexico 
(n= 100) and Brazil (n= 101) valued each health state using the TTO methodol-
ogy. Results: Participants showed a clear preference for the treatment response 
states; CR was valued as the state least likely to affect HRQL, with utility gains 
of 0.13–0.14 over stable disease. The experience of any AE was associated with a 
large decline in quality of life. The most burdensome AEs were acute GVHD and 
grade III PSN. Experiencing acute GVHD gave a disutility from stable disease of 
0.190 (for Brazil) and 0.125 (for Mexico). Only minor discrepancies existed between 
the mean utilities for the two countries, the largest being for PR (Mexico, 0.633; 
Brazil, 0.717). cOnclusiOns: Societal valuation of health states for R/R HL and 
sALCL revealed the notable perceived benefit of a treatment response and the 
significant disutility associated with AE experience. Utility values for Mexico and 
Brazil were broadly consistent.
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utility values foR PatieNts with advaNCed gastRoiNtestiNal 
stRomal tumoRs (gist) tReated with RegoRafeNiB veRsus PlaCeBo iN 
the Phase iii gRid tRial
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Objectives: To estimate utility values by health states for regorafenib and placebo-
treated subjects from the phase-3 GIST – Regorafenib In Progressive Disease (GRID) 
trial, and test the assumption that utility values remained constant over successive 
